Predicting the response to neoadjuvant chemotherapy. Can the addition of tomosynthesis improve the accuracy of contrast-enhanced spectral mammography? A comparison with breast MRI
The British Journal of Radiology · 2023-08 · 96 (1148)
DOI: 10.1259/bjr.20220921 ↗Kurz gefasst
Fachartikel in der Zeitschrift The British Journal of Radiology, 2023-08. Verfasst von Sarah L Savaridas und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Dundee, Dundee, United Kingdom. Hauptthemen laut MEDLINE: Breast Neoplasms, Breast Diseases, Calcinosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objectives
Image monitoring is essential to monitor response to neoadjuvant chemotherapy (NACT). Whilst breast MRI is the gold-standard technique, evidence suggests contrast-enhanced spectral mammography (CESM) is comparable. We investigate whether the addition of digital breast tomosynthesis (DBT) to CESM increases the accuracy of response prediction.
Methods
Women receiving NACT for breast cancer were included. Imaging with CESM+DBT and MRI was performed post-NACT. Imaging appearance was compared with pathological specimens. Accuracy for predicting pathological complete response (pCR) and concordance with size of residual disease was calculated.
Results
Sixteen cancers in 14 patients were included, 10 demonstrated pCR. Greatest accuracy for predicting pCR was with CESM enhancement (accuracy: 81.3%, sensitivity: 100%, specificity: 57.1%), followed by MRI (accuracy: 62.5%, sensitivity: 44.4%, specificity: 85.7%). Concordance with invasive tumour size was greater for CESM enhancement than MRI, concordance-coefficients 0.70 vs 0.66 respectively. MRI demonstrated greatest concordance with whole tumour size followed by CESM+microcalcification, concordance coefficients 0.86 vs 0.69. DBT did not improve accuracy for prediction of pCR or residual disease size. CESM+DBT underestimated size of residual disease, MRI overestimated but no significant differences were seen (p>0.05).
Conclusions
CESM is similar to MRI for predicting residual disease post-NACT. Size of enhancement alone demonstrates best concordance with invasive disease. Inclusion of residual microcalcification improves concordance with ductal carcinoma in situ. The addition of DBT to CESM does not improve accuracy. Advances in knowledge The addition ofDBT to CESM does not improve NACT response prediction. CESM enhancement has greatest accuracy for residual invasive disease, CESM+calcification has greater accuracy for residual in situ disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Dundee, Dundee, United Kingdom.
- NHS Tayside, Dundee, United Kingdom.
- Gloucestershire Hospitals, NHS Foundation Trust, Gloucester, United Kingdom.
Zitieren
APA
Savaridas, S. L., Vinnicombe, S. J., Warwick, V., & Evans, A. (2023). Predicting the response to neoadjuvant chemotherapy. Can the addition of tomosynthesis improve the accuracy of contrast-enhanced spectral mammography? A comparison with breast MRI. The British Journal of Radiology, 96(1148). https://doi.org/10.1259/bjr.20220921
Vancouver
Savaridas SL, Vinnicombe SJ, Warwick V, Evans A. Predicting the response to neoadjuvant chemotherapy. Can the addition of tomosynthesis improve the accuracy of contrast-enhanced spectral mammography? A comparison with breast MRI. The British Journal of Radiology. 2023;96(1148). doi:10.1259/bjr.20220921
BibTeX
@article{Savaridas2023,
author = {Savaridas, Sarah L and Vinnicombe, Sarah J and Warwick, Violet and Evans, Andrew},
title = {Predicting the response to neoadjuvant chemotherapy. Can the addition of tomosynthesis improve the accuracy of contrast-enhanced spectral mammography? A comparison with breast MRI},
journal = {The British Journal of Radiology},
year = {2023},
volume = {96},
number = {1148},
doi = {10.1259/bjr.20220921}
}
EUVIMED